Page 96 - Read Online

Page 244 Van Der Steen et al. Cancer Drug Resist 2018;1:230-49 I http://dx.doi.org/10.20517/cdr.2018.13

synthesis. Proc Natl Acad Sci U S A 1994;91:6967-71.
21. Deb TB, Su L, Wong L, Bonvini E, Wells a, David M, Johnson GR. Epidermal growth factor (EGF) receptor kinase-independent
signaling by EGF. J Biol Chem 2001;276:15554-60.
22. Weihua Z, Tsan R, Huang WC, Wu Q, Chiu CH, Fidler IJ, Hung MC. Survival of cancer cells is maintained by EGFR independent of its
kinase activity. Cancer Cell 2008;13:385-93.
23. Zhu H, Cao X, Ali-Osman F, Keir S, Lo HW. EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of
PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity. Cancer Lett 2010;294:101-10.
24. Irwin ME, Bohin N, Boerner JL. Src family kinases mediate epidermal growth factor receptor signaling from lipid rafts in breast cancer
cells. Cancer Biol Ther 2011;12:718-26.
25. Irwin ME, Mueller KL, Bohin N, Ge Y, Boerner JL. Lipid raft localization of EGFR alters the response of cancer cells to the EGFR
tyrosine kinase inhibitor gefitinib. J Cell Physiol 2011;226:2316-28.
26. Murray S, Dahabreh IJ, Linardou H, Manoloukos M, Bafaloukos D, Kosmidis P. Somatic mutations of the tyrosine kinase domain of
epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database. J
Thorac Oncol 2008;3:832-9.
27. Cho J, Chen L, Sangji N, Okabe T, Yonesaka K, Francis JM, Flavin RJ, Johnson W, Kwon J, Yu S, Greulich H, Johnson BE, Eck MJ,
Jänne PA, Wong KK, Meyerson M. Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric
dimerization. Cancer Res 2013;73:6770-9.
28. Rajasekaran R, Sethumadhavan R. In silico identification of significant detrimental missense mutations of EGFR and their effect with
4-anilinoquinazoline-based drugs. Appl Biochem Biotechnol 2010;160:1723-33.
29. Jiang J, Greulich H, Jänne PA, Sellers WR, Meyerson M, Griffin JD. Epidermal growth factor-independent transformation of Ba/
F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res
2005;65:8968-74.
30. Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe
Y, Yang J-J, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin-paclitaxel in
pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
31. Zhao J, Chen M, Zhong W, Zhang L, Li L, Xiao Y, Nie L, Hu P, Wang M. Cerebrospinal fluid concentrations of gefitinib in patients with
lung adenocarcinoma. Clin Lung Cancer 2013;14:188-93.
32. de Vries NA, Buckle T, Zhao J, Beijnen JH, Schellens JH, van Tellingen O. Restricted brain penetration of the tyrosine kinase inhibitor
erlotinib due to the drug transporters P-gp and BCRP. Invest New Drugs 2012;30:443-9.
33. Hoffknecht P1, Tufman A, Wehler T, Pelzer T, Wiewrodt R, Schütz M, Serke M, Stöhlmacher-Williams J, Märten A, Maria Huber R,
Dickgreber NJ; Afatinib Compassionate Use Consortium (ACUC). Efficacy of the irreversible ErbB family blocker afatinib in epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or
leptomeningeal disease. J Thorac Oncol 2015;10:156-63.
34. Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C, Kraemer O, Himmelsbach F, Haaksma E, Adolf GR. Target binding
properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 2012;343:342-50.
35. Jin Y, Shao Y, Shi X, Lou G, Zhang Y, Wu X, Tong X, Yu X. Mutational profiling of non-small-cell lung cancer patients resistant to first-
generation EGFR tyrosine kinase inhibitors using next generation sequencing. Oncotarget 2016;7:61755-63.
36. Engle JA, Kolesar JM. Afatinib: a first-line treatment for selected patients with metastatic non-small-cell lung cancer. Am J Health Syst
Pharm 2014;71:1933-8.
37. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska
FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying
responsiveness of non–small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
38. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y,
Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
Science 2004;304:1497-500.
39. Yun C-H, Mengwasser KE, Toms A V, Woo MS, Greulich H, Wong K-K, Meyerson M, Eck MJ. The T790M mutation in EGFR kinase
causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008;105:2070-5.
40. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR, Fidias P, Lynch TJ,
Rabindran SK, McGinnis JP, Wissner A, Sharma S V, Isselbacher KJ, Settleman J, Haber DA. Irreversible inhibitors of the EGF receptor
may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci 2005;102:7665-70.
41. Katakami N, Atagi S, Goto K, Hida T, Horai T, Inoue A, Ichinose Y, Koboyashi K, Takeda K, Kiura K, Nishio K, Seki Y, Ebisawa R,
Shahidi M, Yamamoto N. LUX-lung 4: a phase ii trial of afatinib in patients with advanced non-small-cell lung cancer who progressed
during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol 2013;31:3335-41.
42. Van Der Steen N, Caparello C, Rolfo C, Pauwels P, Peters GJ, Giovannetti E. New developments in the management of non-small-cell
lung cancer , focus on rociletinib: what went wrong? Onco Targets Ther 2016;9:6065-74.
43. Cross DAE, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR V, Ward RA, Mellor MJ, Hughes
G, Rahi A, Jacobs VN, Brewer MR, Ichihara E, Sun J, Jin H, Ballard P, Al-Kadhimi K, Rowlinson R, Klinowska T, Richmond GHP,
Cantarini M, Kim DW, Ranson MR, Pao W. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR
inhibitors in lung cancer. Cancer Discov 2014;4:1046-61.
44. Goss G, Tsai CM, Shepherd FA, Ahn MJ, Bazhenova L, Crinò L, de Marinis F, Felip E, Morabito A, Hodge R, Cantarini M, Johnson M,